Keeping Cell Therapy Clinicals On The Rails With Brian Culley
Source: Bioprocess Online
![20_12_BPO_BusBiotech_CGMiniseries_Social_ep30 20_12_BPO_BusBiotech_CGMiniseries_Social_ep30](https://vertassets.blob.core.windows.net/image/4785cce8/4785cce8-0f31-4e91-960e-613c43982eb5/375_250-20_12_bpo_busbiotech_cgminiseries_social_ep30.png)
Like most biotechs, Lineage Cell Therapeutics faced some significant challenges as it navigated multiple clinical trials, one of them in an aging, at-risk population, during a global pandemic. On this episode, CEO Brian Culley tells Erin Harris and Matt Pillar how he kept the company's programs for OpRegen® (dry AMD with GA) and OPC1 (acute spinal cord injury) running on time despite the disruptions.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more